| abstract |
The present invention provides methods for increasing expression of cell surface molecules of CD5 + B cell lymphoma cells by contacting cells with immune response modifiers. The invention also provides methods for the treatment of CD5 + B cell lymphomas, including chronic lymphocytic leukemia and small lymphocytic lymphoma, by administering immune response modifier compounds to a subject in need of such treatment. Suitable immune response modifier compounds include agonists of TLR7 and/or TLR8. |